Literature DB >> 15737812

Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms.

Kristina B Svendsen1, Steen Andersen, Sigurdur Arnason, Staffan Arnér, Harald Breivik, Tarja Heiskanen, Eija Kalso, Ulf E Kongsgaard, Per Sjogren, Peter Strang, Flemming W Bach, Troels S Jensen.   

Abstract

Breakthrough pain or transient worsening of pain in patients with an ongoing steady pain is a well known feature in cancer pain patients, but it is also seen in non-malignant pain conditions with involvement of nerves, muscles, bones or viscera. Continuous and intermittent pain seems to be a general feature of these different pain conditions, and this raises the possibility of one or several common mechanisms underlying breakthrough pain in malignant and non-malignant disorders. Although the mechanisms of spontaneous ongoing pain and intermittent flares of pain (BTP) may be difficult to separate, we suggest that peripheral and/or central sensitization (hyperexcitability) may play a major role in many causes of BTP. Mechanical stimuli (e.g. micro-fractures) changes in chemical environments and release of tumour growth factors may initiate sensitization both peripherally and centrally. It is suggested that sensitization could be the common denominator of BTP in malignant and non-malignant pain.

Entities:  

Mesh:

Year:  2005        PMID: 15737812     DOI: 10.1016/j.ejpain.2004.06.001

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  49 in total

Review 1.  Substance abuse in cancer pain.

Authors:  Tatiana D Starr; Lauren J Rogak; Steven D Passik
Journal:  Curr Pain Headache Rep       Date:  2010-08

2.  Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.

Authors:  Lukas Radbruch; Luis M Torres; John E Ellershaw; Antonio Gatti; Guillermo Luis Lerzo; Julia Revnic; Donald Taylor
Journal:  Support Care Cancer       Date:  2011-03-22       Impact factor: 3.603

Review 3.  [Cancer breakthrough pain. Indications for rapidly effective opioids].

Authors:  J Kessler; H J Bardenheuer
Journal:  Anaesthesist       Date:  2011-07       Impact factor: 1.041

4.  Cancer pain--progress and ongoing issues in Europe.

Authors:  Stein Kaasa; Sebastiano Mercadante; Augusto Caraceni
Journal:  Pain Res Manag       Date:  2009 Sep-Oct       Impact factor: 3.037

5.  Understanding the Chameleonic Breakthrough Cancer Pain.

Authors:  Sebastiano Mercadante; Russell K Portenoy
Journal:  Drugs       Date:  2021-01-30       Impact factor: 9.546

Review 6.  Idiopathic breakthrough pain: a new hypothesis.

Authors:  Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 7.  Management of breakthrough pain in patients with cancer.

Authors:  Leeroy William; Rod Macleod
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  [Cancer pain therapy].

Authors:  F Nauck
Journal:  Urologe A       Date:  2009-10       Impact factor: 0.639

9.  Breakthrough cancer pain: review of prevalence, characteristics and management.

Authors:  Seema Mishra; Sushma Bhatnagar; Prakash Chaudhary; Shiv Pratap Singh Rana
Journal:  Indian J Palliat Care       Date:  2009-01

Review 10.  Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain.

Authors:  J Devulder; A Jacobs; U Richarz; H Wiggett
Journal:  Br J Anaesth       Date:  2009-09-06       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.